Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

PHASE3CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

June 30, 2017

Conditions
Influenza, Human
Interventions
BIOLOGICAL

NBP607-QIV

For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]

BIOLOGICAL

NBP607-TIV

For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]

Trial Locations (12)

Unknown

Korea University ANSAN hospital, Ansan

Chungnam National University Hospital, Daejeon

Inje University Ilsan Paik Hospital, Goyang

Gachon University Gil Medical center, Incheon

The Catholic University of Korea, Incheon ST. Mary's Hospital, Incheon

Chonbuk National University Hospital, Jeonju

Asan Medical Center, Seoul

Eulji General Hospital, Seoul

Hallym University Dongtan Sacred Heart Hospital, Seoul

Korea Institute of Radiological and Medical Science, Seoul

Samsung Medical Center, Seoul

Wonju Severance Christian Hospital, Wŏnju

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT03020628 - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months | Biotech Hunter | Biotech Hunter